MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

Met, metastasis, motility and more

Birchmeier, C., Birchmeier, W., Gherardi, E., & Woude, G. F. V. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,652

Circular binary segmentation for the analysis of array-based DNA copy number data

Olshen, A. B., Venkatraman, E. S., Lucito, R., & Wigler, M. H. (2004) · Biostatistics · doi:10.1093/biostatistics/kxh008 · Cited by 2,304

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

Schmidt, L. S., Duh, F.-M. C., Chen, F., Kishida, T., Glenn, G. M., Choyke, P. L., Scherer, S. W., Zhuang, Z., Lubensky, I. A., Dean, M. C., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-68 · Cited by 1,517

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

Kwak, E. L., Sordella, R., Bell, D. W., Godin-Heymann, N., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Driscoll, D. R., Fidias, P. M., Lynch, T. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502860102 · Cited by 966

Analysis of Compound Synergy in High-Throughput Cellular Screens by Population-Based Lifetime Modeling

Peifer, M., Weiss, J. M., Sos, M. L., Koker, M., Heynck, S., Netzer, C., Fischer, S., Rode, H. B., Rauh, D., Rahnenführer, J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008919 · Cited by 24

An Autopsy Case of Two Distinct, Acquired Drug Resistance Mechanisms in Epidermal Growth Factor Receptor-mutant Lung Adenocarcinoma: Small Cell Carcinoma Transformation and Epidermal Growth Factor Receptor T790M Mutation

Furugen, M., Uechi, K., Hirai, J., Aoyama, H., Saio, M., Yoshimi, N., Kinjo, T., Miyagi, K., Haranaga, S., Higa, F., et al. (2015) · Internal Medicine · doi:10.2169/internalmedicine.54.5481 · Cited by 23

Emerging Targets in Advanced Non-Small-Cell Lung Cancer

Valentino, F., Borra, G., Allione, P., & Rossi, L. (2018) · Future Oncology · doi:10.2217/fon-2018-0099 · Cited by 23

Brain Metastases from Lung Cancer: Is MET an Actionable Target?

Stella, G. M., Corino, A., Berzero, G., Kolling, S., Filippi, A. R., & Benvenuti, S. (2019) · Cancers · doi:10.3390/cancers11030271 · Cited by 23

A novel non-agonist c-Met antibody drug conjugate with superior potency over a c-Met tyrosine kinase inhibitor in c-Met amplified and non-amplified cancers

Fujita, R., Blot, V., Wong, E., Stewart, C., Lieuw, V., Richardson, R., Banah, A., Villicana, J., Timmer, A. M., Coronella, J. A., et al. (2020) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1737490 · Cited by 23

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non‐small cell lung cancer patients

Zheng, Q., Hong, S., Huang, Y., Zhao, H., Yang, Y., Hou, X., Zhao, Y., Ma, Y., Zhou, T., Zhang, Y., et al. (2020) · Clinical and Translational Medicine · doi:10.1186/s40169-020-0269-y · Cited by 23

Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models

Marrocco, I., Romaniello, D., Vaknin, I., Garcia, D. D., Oren, R., Uribe, M. L., Nataraj, N. B., Ghosh, S., Eilam, R., Salame, T., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013144 · Cited by 23

Bioinformatically Expanded Next-Generation Sequencing Analysis Optimizes Identification of Therapeutically Relevant MET Copy Number Alterations in >50,000 Tumors

Solomon, J. P., Yang, S., Choudhury, N. J., Ptashkin, R. N., Eslamdoost, N., Falcon, C. J., Martin, A. S., Plodkowski, A. J., Wilhelm, C., Shen, R., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1321 · Cited by 23

EHMT2-mediated transcriptional reprogramming drives neuroendocrine transformation in non–small cell lung cancer

Yang, C., Ma, S., Zhang, J., Han, Y., Wan, L., Zhou, W., Dong, X., Yang, W., Chen, Y., Gao, L., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2317790121 · Cited by 23

Irreversible EGFR-TKIs: dreaming perfection.

Landi, L. M., & Cappuzzo, F. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2012.12.05 · Cited by 25

Intermittent high-dose treatment with erlotinib enhances therapeutic efficacy in EGFR-mutant lung cancer

Schöttle, J., Chatterjee, S., Volz, C., Siobal, M., Florin, A., Rokitta, D., Hinze, Y., Dietlein, F., Plenker, D., König, K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6276 · Cited by 22

Dual transcript and protein quantification in a massive single cell array

Park, S.-M., Lee, J. Y., Hong, S., Lee, S. H., Dimov, I. K., Lee, H., Suh, S., Pan, Q., Li, K., Wu, A. M., et al. (2016) · Lab on a Chip · doi:10.1039/c6lc00762g · Cited by 23

The Met tyrosine kinase receptor as a therapeutic target and a potential cancer stem cell factor responsible for therapy resistance

Miękus, K. (2016) · Oncology Reports · doi:10.3892/or.2016.5297 · Cited by 23

Applications of liquid biopsy in lung cancer-diagnosis, prognosis prediction, and disease monitoring.

Luo, W., Rao, M., Qu, J., & Luo, D. (2018) · Europe PMC (PubMed Central) · Cited by 23

Synthesis and structure–activity relationship of aminopyridines with substituted benzoxazoles as c-Met kinase inhibitors

Lee, J., Han, S., Jung, H., Yang, J., Choi, J.-W., Chae, C. H., Park, C. H., Choi, S. U., Lee, K., Ha, J. D., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.04.083 · Cited by 23

Short-hairpin RNA library: identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer

Sudo, M., Mori, S., Madan, V., Yang, H. H., Leong, G., & Koeffler, H. P. (2014) · Oncotarget · doi:10.18632/oncotarget.2891 · Cited by 24

Targeting c-MET Alterations in Cancer: A Review of Genetic Drivers and Therapeutic Implications

Ji, M., Ganesan, S., Xia, B., & Huo, Y. (2025) · Cancers · doi:10.3390/cancers17091493 · Cited by 22

Mutations of the epidermal growth factor receptor gene in NSCLC patients

Han, B., ZHOU, X., Zhang, R., Zang, W., CHEN, Z.-Y., Song, H., Wan, H., & Zheng, C. (2011) · Oncology Letters · doi:10.3892/ol.2011.366 · Cited by 23

MET: A New Promising Biomarker in Non-Small-Cell Lung Carcinoma

Pérez-Ramírez, C., Cañadas‐Garre, M., Jiménez‐Varo, E., Faus-Dáder, M. J., & Calleja‐Hernández, M. Á. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.11 · Cited by 23

Clinical Application of Picodroplet Digital PCR Technology for Rapid Detection of EGFR T790M in Next-Generation Sequencing Libraries and DNA from Limited Tumor Samples

Borsu, L. A., Intrieri, J., Thampi, L. M., Yu, H. A., Riely, G. J., Nafa, K., Chandramohan, R., Ladanyi, M., & Arcila, M. E. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.07.004 · Cited by 22

Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer

Corallo, S., D’Argento, E., Strippoli, A., Basso, M., Monterisi, S., Rossi, S., Cassano, A., & Barone, C. M. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0479-4 · Cited by 22

Engineering Multidimensional Evolutionary Forces to Combat Cancer

McCoach, C. E., & Bivona, T. G. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1196 · Cited by 23

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation

Brazel, D., Zhang, S. S., & Nagasaka, M. (2022) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s360574 · Cited by 22

Targeting the MET pathway for potential treatment of NSCLC

Li, A., Gao, H., & Wu, Y.-L. L. C. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.995093 · Cited by 22

Molecular Markers with Predictive and Prognostic Relevance in Lung Cancer

Rose-James, A., & Sreelekha, T. T. (2012) · Lung Cancer International · doi:10.1155/2012/729532 · Cited by 23

Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer

He, C., Zheng, L., Xu, Y., Liu, M., Li, Y., & Xu, J. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.07.012 · Cited by 22

Molecular determinants of lung cancer metastasis to the central nervous system.

Whitsett, T. G., Inge, L. J., Dhruv, H., Cheung, P. Y.-C., Weiss, G. J., Bremner, R. M., Winkles, J. A., & Tran, N. L. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.03.12 · Cited by 22

The apoptotic effect of simvastatin via the upregulation of BIM in nonsmall cell lung cancer cells

Lee, H. Y., Kim, I. K., Lee, H. I., Mo, J. Y., Yeo, C. D., Kang, H. H., Moon, H. S., & Lee, S. H. (2016) · Experimental Lung Research · doi:10.3109/01902148.2015.1125970 · Cited by 22

Genomic aberrations of MDM 2, MDM 4, FGFR 1 and FGFR 3 are associated with poor outcome in patients with salivary gland cancer

Ach, T., Schwarz‐Furlan, S., Ach, S., Agaimy, A., Gerken, M., Rohrmeier, C., Zenk, J., Iro, H., Brockhoff, G., & Ettl, T. (2015) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12394 · Cited by 22

Broad-spectrum receptor tyrosine kinase inhibitors overcome de novo and acquired modes of resistance to EGFR-targeted therapies in colorectal cancer

Graves‐Deal, R., Bogatcheva, G. T., Rehman, S., Lu, Y., Higginbotham, J. N., & Singh, B. (2019) · Oncotarget · doi:10.18632/oncotarget.26663 · Cited by 22

Cyclosporine A sensitizes lung cancer cells to crizotinib through inhibition of the Ca2+/calcineurin/Erk pathway

Liu, Z., Jiang, L., Li, Y., Xie, B., Xie, J., Wang, Z., Zhou, X., Jiang, H., Fang, Y., Pan, H., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.019 · Cited by 22

Combined inhibition of MET and VEGF enhances therapeutic efficacy of EGFR TKIs in EGFR-mutant non-small cell lung cancer with concomitant aberrant MET activation

Huang, S., Long, Y., Gao, Y., Lin, W., Wang, L., Jiang, J., Yuan, X., Chen, Y., Zhang, P., & Chu, Q. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00565-9 · Cited by 23

Quantification and localization of oncogenic receptor tyrosine kinase variant transcripts using molecular inversion probes

van den Heuvel, C. N. A. M., Das, A., de Bitter, T. J. J., Simmer, F., Wurdinger, T. D., Molina‐Vila, M. Á., & Leenders, W. P. J. (2018) · Scientific Reports · doi:10.1038/s41598-018-25328-5 · Cited by 21

Therapeutic bronchoscopy in the era of genotype directed lung cancer management

Mohan, A., Harris, K. N., Bowling, M., Brown, C., & Hohenforst‐Schmidt, W. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.08.14 · Cited by 22

Genotype-determined EGFR-RTK heterodimerization and its effects on drug resistance in lung Cancer treatment revealed by molecular dynamics simulations

Zhu, M., Wang, D. D., & Yan, H. (2021) · BMC Molecular and Cell Biology · doi:10.1186/s12860-021-00358-6 · Cited by 21

Rebiopsy in advanced non-small cell lung cancer, clinical relevance and prognostic implications

Scheffler, M., Wiesweg, M., Michels, S. Y. F., Nogová, L., Kron, A., Herold, T., Scheel, A. H., Metzenmacher, M., Eberhardt, W., Reis, H., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.04.006 · Cited by 21

Strategies for Overcoming Acquired Resistance to Epidermal Growth Factor Receptor–Targeted Therapies in Lung Cancer

Oxnard, G. R. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0254-ra · Cited by 21

Novel therapeutic target for head and neck squamous cell carcinoma

Lau, P., & Chan, A. T. �. (2010) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328341879d · Cited by 21

EGFR-Mutant Lung Adenocarcinomas Treated First-Line with the Novel EGFR Inhibitor, XL647, Can Subsequently Retain Moderate Sensitivity to Erlotinib

Chmielecki, J., Pietanza, M. C., Aftab, D. T., Shen, R., Zhao, Z., Chen, X., Hutchinson, K. E., Viale, A. J., Kris, M. G., Stout, T. J., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31823c5aee · Cited by 21

Overcoming Molecular Mechanisms of Resistance to First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Bar, J., & Onn, A. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.09.001 · Cited by 21

ZNF32 contributes to the induction of multidrug resistance by regulating TGF-β receptor 2 signaling in lung adenocarcinoma

Li, J., Ao, J., Li, K., Zhang, J., Li, Y., Zhang, L., Wei, Y., Gong, D., Gao, J., Tan, W., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.328 · Cited by 21

Targeting HSF1 as a Therapeutic Strategy for Multiple Mechanisms of EGFR Inhibitor Resistance in EGFR Mutant Non-Small-Cell Lung Cancer

Lee, S., Jung, J., Lee, Y., Kim, S., Kim, J., Kim, B., Park, K. C., Kwon, B., & Han, D. C. (2021) · Cancers · doi:10.3390/cancers13122987 · Cited by 21

An intramolecular G-quadruplex structure formed in the humanMETpromoter region and its biological relevance

Yan, J. Y., Zhao, X., Liu, B., Yuan, Y., & Guan, Y. (2015) · Molecular Carcinogenesis · doi:10.1002/mc.22330 · Cited by 21

Targeted Therapy for Advanced Non-small Cell Lung Cancers: Historical Perspective, Current Practices, and Future Development

Mahalingam, D., Mita, A. C., Mita, M. M., Nawrocki, S. T., & Giles, F. J. (2009) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2009.03.001 · Cited by 21

Novel insights into the molecular origins and treatment of lung cancer

Webb, J. D., & Simon, M. C. (2010) · Cell Cycle · doi:10.4161/cc.9.20.13588 · Cited by 21

Comparison of the c‐MET gene amplification between primary tumor and metastatic lymph nodes in non‐small cell lung cancer

Xu, C., Wang, W., Wu, M., Zhu, Y., Zhuang, W., Lin, G., Du, K., Huang, Y., Chen, Y., Chen, G., et al. (2017) · Thoracic Cancer · doi:10.1111/1759-7714.12455 · Cited by 21

Current Challenges and Future Directions

Matthews, D., & Gerritsen, M. E. (2010) · Wiley eBooks · doi:10.1002/9780470555293.ch11 · Cited by 21

Integrated multi‐omics data analyses for exploring the co‐occurring and mutually exclusive gene alteration events in colorectal cancer

Zhou, Y., Cheng, X., Zhang, F., Chen, Q., Chen, X., Shen, Y., Lai, C., Kota, V. G., Sun, W., Huang, Q., et al. (2020) · Human Mutation · doi:10.1002/humu.24059 · Cited by 20

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer

Weickhardt, A. J., Lau, D. K., Hodgson‐Garms, M., Lavis, A., Jenkins, L. J., Vukelic, N., Ioannidis, P., Luk, I. Y., & Mariadason, J. M. (2022) · BMC Cancer · doi:10.1186/s12885-022-09478-4 · Cited by 20

Opportunities and challenges of targeting c-Met in the treatment of digestive tumors

Zhang, Z., Li, D., Yun, H., Tong, J., Liu, W., Chai, K., Zeng, T., Gao, Z., & Xie, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.923260 · Cited by 20

Therapeutic strategies for non-small cell lung cancer: Experimental models and emerging biomarkers to monitor drug efficacies

Bourreau, C., Treps, L., Faure, S., Fradin, D., & Clere, N. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108347 · Cited by 20

Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment

Kim, H.-R., Lee, J. C., Kim, Y., Kim, K. S., Oh, I., Lee, S. Y., Jang, T. W., Lee, M. K., Shin, K. C., Lee, G. H., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.008 · Cited by 21

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy

Yoshimura, K., Inui, N., Karayama, M., Inoue, Y., Enomoto, N., Fujisawa, T., Nakamura, Y., Takeuchi, K., Sugimura, H., & Suda, T. (2017) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2017.02.009 · Cited by 20

Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma

Wang, J., Mirzapoiazova, T., Tan, Y. C., Pang, K. M., Pozhitkov, A. E., Wang, Y., Wang, Y., Mambetsariev, B., Wang, W., Nasser, M. W., et al. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1472193 · Cited by 20

Acquired Resistance in Lung Cancer

Tulpule, A., & Bivona, T. G. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033502 · Cited by 21

Scaffold-based design of kinase inhibitors for cancer therapy

Zhang, C., & Bollag, G. E. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.10.010 · Cited by 20

Lipid metabolic pathways as lung cancer therapeutic targets: A computational study

Yano, K. (2011) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2011.876 · Cited by 20

From genomic landscapes to personalized cancer management—is there a roadmap?

Swanton, C., & Caldas, C. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05776.x · Cited by 19

SELPHI: correlation-based identification of kinase-associated networks from global phospho-proteomics data sets

Petsalaki, E., Helbig, A. O., Gopal, A., Pasculescu, A., Roth, F. P., & Pawson, T. J. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv459 · Cited by 19

Chemotherapeutics-resistance “arms” race: An update on mechanisms involved in resistance limiting EGFR inhibitors in lung cancer

Singh, P. K., & Silakari, O. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.08.001 · Cited by 20

Engineered Bifunctional Proteins for Targeted Cancer Therapy: Prospects and Challenges

Du, Y., & Xu, J. (2021) · Advanced Materials · doi:10.1002/adma.202103114 · Cited by 19

Detection of MET amplification by droplet digital PCR in peripheral blood samples of non-small cell lung cancer

Fan, Y., Sun, R., Wang, Z., Zhang, Y., Xiao, X., Liu, Y., Xin, B., Xiong, H., Lu, D., & Ma, J. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04048-4 · Cited by 19

Targeting MET Amplification: Opportunities and Obstacles in Therapeutic Approaches

Kumaki, Y., Oda, G., & Ikeda, S. (2023) · Cancers · doi:10.3390/cancers15184552 · Cited by 20

MLH1V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients withEGFRL858R-positive lung adenocarcinoma

Chiu, C., Ho, H., Doong, H., Yeh, Y., Chen, M., Chou, T., & Tsai, C. (2015) · Oncotarget · doi:10.18632/oncotarget.3511 · Cited by 19

AURKA upregulation plays a role in fibroblast-reduced gefitinib sensitivity in the NSCLC cell line HCC827

CHEN, J., Lu, H. Y., Wang, Z., Yin, H., Zhu, L., Liu, C., Zhang, P., Hu, H., Yang, Y., & Han, H. (2015) · Oncology Reports · doi:10.3892/or.2015.3764 · Cited by 19

FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion

Whitsett, T. G., Ensign, S. P. F., Dhruv, H., Inge, L. J., Kurywchak, P. A., Wolf, K. K., Lobello, J. R., Kingsley, C. B., Allen, J. W., Weiss, G. J., et al. (2014) · Clinical & Experimental Metastasis · doi:10.1007/s10585-014-9653-6 · Cited by 19

Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines

Holland, W. S., Chinn, D. C., Lara, P. N., Gandara, D. R., & Mack, P. C. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1855-4 · Cited by 19

BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations

Huang, W. F., Liu, A. H., Zhao, H. J., Dong, H., Liu, L. Y., & Cai, S. X. (2015) · Medicine · doi:10.1097/md.0000000000001263 · Cited by 19

Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non–Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance

McCoach, C. E., Bivona, T. G., Blakely, C. M., & Doebele, R. C. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.05.025 · Cited by 19

FOXM1 confers resistance to gefitinib in lung adenocarcinoma via a MET/AKT-dependent positive feedback loop

Wang, Y., Zhang, W., Wen, L., Yang, H., Wen, M., Yun, Y., Zhao, L., Zhu, X., Li, T. X., Luo, E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11043 · Cited by 19

Molecular Testing Strategies for Pulmonary Adenocarcinoma: An Optimal Approach With Cost Analysis

Layfield, L. J., Hammer, R., White, S., Furtado, L. V., & Schmidt, R. L. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0218-oa · Cited by 19

Non–Small Cell Lung Cancer as a Precision Oncology Paradigm: Emerging Targets and Tumor Mutational Burden (TMB)

Tafe, L. J. (2019) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000244 · Cited by 19

Compound 15c, a Novel Dual Inhibitor of EGFRL858R/T790M and FGFR1, Efficiently Overcomes Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance of Non-Small-Cell Lung Cancers

Chen, G., Bao, Y., Weng, Q., Zhao, Y., Lu, X., Fu, L., Chen, L., Liu, Z., Zhang, X., & Liang, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01533 · Cited by 19

Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR -mutant lung cancer

Eser, P. Ö., Paranal, R. M., Son, J., Ivanova, E. V., Kuang, Y., Haikala, H. M., To, C., Okoro, J. J., Dholakia, K. H., Choi, J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb3738 · Cited by 19

Resistance mechanisms of tumour cells to EGFR inhibitors

Morgillo, F., Cantile, F., Fasano, M., Troiani, T., Martinelli, E., & Ciardiello, F. (2009) · Clinical & Translational Oncology · doi:10.1007/s12094-009-0354-6 · Cited by 19

Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non–Small Cell Lung Cancer Detected by 18F-fluorothymidine

Iommelli, F., Rosa, V. D., Terlizzi, C., Monti, M., Panico, M., Fonti, R., & Vecchio, S. D. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3657 · Cited by 19

Clinical Development of Phosphatidylinositol-3 Kinase Pathway Inhibitors

Arteaga, C. L. (2010) · Current topics in microbiology and immunology · doi:10.1007/82_2010_54 · Cited by 19

Trials to Overcome Drug Resistance to EGFR and ALK Targeted Therapies – Past, Present, and Future

Spaans, J. N., & Goss, G. D. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00233 · Cited by 19

Comprehensive Genomic Profiling of Circulating Cell-Free DNA Distinguishes Focal MET Amplification from Aneuploidy in Diverse Advanced Cancers

Kumaki, Y., Olsen, S., Suenaga, M., Nakagawa, T., Uetake, H., & Ikeda, S. (2021) · Current Oncology · doi:10.3390/curroncol28050317 · Cited by 18

A programmed cell death-related model based on machine learning for predicting prognosis and immunotherapy responses in patients with lung adenocarcinoma

Zhang, Y., Wang, Y., Chen, J., Xia, Y., & Huang, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1183230 · Cited by 18

MET inhibition in lung cancer.

Menis, J., Levra, M. G., & Novello, S. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2012.12.04 · Cited by 17

The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations

Riely, G. J. (2008) · Lung Cancer · doi:10.1016/s0169-5002(08)70101-6 · Cited by 18

Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer

Re, M. D., Vasile, E., Falcone, A., Danesi, R., & Petrini, I. (2014) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2014.908120 · Cited by 18

Afatinib-Based Combination Regimens for the Treatment of Solid Tumors: Rationale, Emerging Strategies and Recent Progress

Bennouna, J., & Vera, S. R. M. (2015) · Future Oncology · doi:10.2217/fon.15.310 · Cited by 18

Identifying EGFR mutation-induced drug resistance based on alpha shape model analysis of the dynamics

Ma, L., Zou, B., & Yan, H. (2016) · Proteome Science · doi:10.1186/s12953-016-0102-0 · Cited by 18

Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells

Yang, Z., Hu, X., Zhang, S., Zhang, W., & Tam, K. Y. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.08.037 · Cited by 18

Targeted Therapies in Non-small-Cell Lung Cancer

Hill, A., Gupta, R. V., Zhao, D., Vankina, R., Amanam, I. U., & Salgia, R. (2019) · Cancer treatment and research · doi:10.1007/978-3-030-16391-4_1 · Cited by 18

Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs

Diao, Z., Han, Y., Zhang, R., & Li, J. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188363 · Cited by 18

MET Amplification (MET/CEP7 Ratio ≥ 1.8) Is an Independent Poor Prognostic Marker in Patients With Treatment-naive Non–Small-cell Lung Cancer

Yin, W. H., Cheng, J., Tang, Z., Törüner, G., Hu, S., Guo, M., Robinson, M. K., Medeiros, L. J., & Tang, G. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.11.002 · Cited by 18

γ Secretase Inhibitor BMS‐708163 Reverses Resistance to EGFR Inhibitor via the PI3K/Akt Pathway in Lung Cancer

Xie, M., He, J., He, C., & Wei, S. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25056 · Cited by 18

Quantifying the sensitivities of EGF receptor (EGFR) tyrosine kinase inhibitors in drug resistant non-small cell lung cancer (NSCLC) cells using hydrogel-based peptide array

Ghosh, G., Yan, X., Lee, A. G., Kron, S. J., & Palecek, S. P. (2010) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2010.07.106 · Cited by 18

Investigation on the 1,6-naphthyridine motif: discovery and SAR study of 1H-imidazo[4,5-h][1,6]naphthyridin-2(3H)-one-based c-Met kinase inhibitors

Wang, Y., Xu, Z., Ai, J., Xia, P., Lin, J., Ji, Y., Geng, M., & Long, Y. (2012) · Organic & Biomolecular Chemistry · doi:10.1039/c2ob26710a · Cited by 18

Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib

Lee, V. H.-F., Leung, D. K. C., Choy, T., Lam, K. O., Lam, P. K. L., Leung, T., & Kwong, D. L. �. (2016) · BMC Cancer · doi:10.1186/s12885-016-2201-9 · Cited by 18

Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression

Tanaka, H., Sakagami, H., Kaneko, N., Konagai, S., Yamamoto, H., Matsuya, T., Yuri, M., Yamanaka, Y., Mori, M., Takeuchi, M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0976 · Cited by 18

Disruption of the EGFR E884–R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity

Tang, Z., Jiang, S., Du, R., Petri, E. T., El-Telbany, A., Chan, P. S. O., Kijima, T., Dietrich, S., Matsui, K., Kobayashi, M., et al. (2008) · Oncogene · doi:10.1038/onc.2008.411 · Cited by 18

Toward Noninvasive Genomic Screening of Lung Cancer Patients

Sequist, L. V. D., Engelman, J. A., & Lynch, T. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.4875 · Cited by 18

Cell-Free DNA Profiling to Discover Mechanisms of Exceptional Response to Cabozantinib Plus Panitumumab in a Patient with Treatment Refractory Metastatic Colorectal Cancer

Jia, J., Morse, M. A., Nagy, R. J., Lanman, R. B., & Strickler, J. H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00305 · Cited by 17

Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer

Jiang, Z., Gu, Z., Yu, X.-M., Cheng, T., & Liu, B. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1447678 · Cited by 22

Usefulness of nanofluidic digital PCR arrays to quantify T790M mutation in EGFR-mutant lung adenocarcinoma.

Isobe, K., Hata, Y., Tochigi, N., Kaburaki, K., Kobayashi, H., Makino, T., Otsuka, H., Ishida, F., Hirota, N., Sano, G., et al. (2015) · PubMed · Cited by 17

Emerging Biomarkers in Personalized Therapy of Lung Cancer

Cagle, P. T., Raparia, K., & Portier, B. P. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_2 · Cited by 16

Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer

Suda, K., Murakami, I., Katayama, T., Tomizawa, K., Osada, H., Sekido, Y., Maehara, Y., Yatabe, Y., & Mitsudomi, T. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1371 · Cited by 206

HGF-MET in Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer

Yano, S., Wang, W., Li, Q., Yamada, T., Takeuchi, S., Matsumoto, K., Nishioka, Y., & Sone, S. (2011) · Current Signal Transduction Therapy · doi:10.2174/157436211795659928 · Cited by 3

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers

Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454

Occurrence of HER2 amplification in EGFR-mutant lung adenocarcinoma with acquired resistence to EGFR-TKIs.

Altavilla, G., Arrigo, C., Tomasello, C., Santarpía, M., Mondello, P., Benecchi, S., & Pitini, V. V. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8047 · Cited by 5

P3.13-14 Identification of Novel Mutations by High-Throughout Sequencing in T790M Wildtype/cMET Unamplified NSCLC with Acquired Resistance to EGFR TKIs

Li, C., Zhang, B., & Wang, C. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.1854